PMID- 15229390
OWN - NLM
STAT- MEDLINE
DCOM- 20041203
LR  - 20181130
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 18
IP  - 3
DP  - 2004 May
TI  - Methods of assessing the functional status of patients with left ventricular 
      systolic dysfunction in interventional studies: can brain natriuretic peptide 
      measurement be used as surrogate for the traditional methods?
PG  - 219-24
AB  - AIM: To review whether brain natriuretic peptides (BNP) can be used as a 
      surrogate for the traditional methods of assessing functional status in 
      interventional studies of patients with left ventricular systolic dysfunction 
      (LVSD). METHODS AND RESULTS: The traditional methods for assessing functional 
      status including New York Heart Association (NYHA) class, exercise intolerance 
      and quality of life were reviewed in relation to BNP measurements in patients 
      with LVSD. A meta-analysis of four studies evaluating BNP levels versus exercise 
      peak oxygen uptake or 6-minute walking distance showed a significant correlation, 
      but a low R-value of -0.59. Studies using BNP levels for optimisation of heart 
      failure therapy showed conflicting results concerning the correlation between the 
      functional improvement and changes in BNP levels. Conflicting results were also 
      found concerning the utility of BNP levels as a surrogate to predict efficacy of 
      the various anti-congestive therapies on heart failure outcome. CONCLUSION: The 
      results of the studies examining BNP measurement as a surrogate for functional 
      status and drug efficacy in patients with LVSD are conflicting. Further studies 
      are necessary to settle the place of BNP measurement as surrogate marker for 
      exercise tolerance, NYHA classification and in assessing efficacy of different 
      interventions in the clinical trials.
FAU - Abdulla, Jawdat
AU  - Abdulla J
AD  - Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark. 
      ja@heart.dk
FAU - Kober, Lars
AU  - Kober L
FAU - Torp-Pedersen, Christian
AU  - Torp-Pedersen C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (Carbazoles)
RN  - 0 (Imidazolidines)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 69PN84IO1A (Enalapril)
RN  - BW7H1TJS22 (imidapril)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
CIN - Cardiovasc Drugs Ther. 2004 May;18(3):181-2. PMID: 15478290
CIN - Cardiovasc Drugs Ther. 2004 Nov;18(6):507; author reply 509. PMID: 15770439
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - *Biomarkers/*blood
MH  - Carbazoles/therapeutic use
MH  - Carvedilol
MH  - Clinical Trials as Topic/methods/statistics & numerical data
MH  - Data Collection/methods
MH  - Drug Administration Schedule
MH  - Enalapril/therapeutic use
MH  - Exercise Test/methods/statistics & numerical data
MH  - Exercise Tolerance/physiology
MH  - *Health Status
MH  - Heart Failure/diagnosis/physiopathology
MH  - Humans
MH  - Imidazolidines/therapeutic use
MH  - Meta-Analysis as Topic
MH  - Metoprolol/therapeutic use
MH  - Natriuretic Peptide, Brain/*blood/chemistry
MH  - Propanolamines/therapeutic use
MH  - Quality of Life
MH  - Statistics as Topic
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/classification/*diagnosis/physiopathology
RF  - 51
EDAT- 2004/07/02 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/07/02 05:00
PHST- 2004/07/02 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/07/02 05:00 [entrez]
AID - 5273647 [pii]
AID - 10.1023/B:CARD.0000033643.93393.46 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2004 May;18(3):219-24. doi: 
      10.1023/B:CARD.0000033643.93393.46.